American Society of Hirudotherapy

Plaque Psoriasis (Localized)

Investigational adjunct, not a primary treatment; a few small, mostly uncontrolled studies report lower PASI scores.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for plaque psoriasis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for plaque psoriasis is investigational.
What evidence exists?
Tier C (investigational). Only a few small studies of leech therapy in psoriasis have been published (a non-randomized comparison of 22 treated and 20 comparison patients in 2012, an uncontrolled series of 34 children in 2022, a conference abstract and two single-patient reports). No blinded randomized controlled trial was identified, so these studies cannot show that leech therapy works. Psoriasis has many highly effective evidence-based treatments — topical corticosteroids, vitamin D analogues, phototherapy (UVB, PUVA), and biologics (IL-17, IL-23, TNF inhibitors) — supported by extensive RCT data and guidelines.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness around plaques for 5 to 10 days
  • Itching and irritation at bite sites for days to weeks
  • Local skin infection or, rarely, Aeromonas infection (heightened with psoriatic skin barrier disruption)
  • Koebner phenomenon — new psoriatic plaques forming at bite sites in some patients
  • Allergic reaction to leech saliva (uncommon)
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • Worsening psoriasis if biologic therapy is interrupted
  • Delay of evidence-based biologic rotation or systemic therapy
  • Post-inflammatory hyperpigmentation, especially in darker skin
Who should not consider this
  • Patients on blood thinners (anticoagulants such as warfarin, DOACs or heparin)
  • Patients with hemophilia or other bleeding disorders
  • Patients with anemia
  • Patients on systemic immunosuppressants or biologics (higher infection risk)
  • Patients with active erythrodermic, pustular, or unstable psoriasis
  • Patients with active skin infection
  • Patients with extensive disease where topical/systemic treatments are clearly indicated
  • Patients with psoriatic arthritis and active joint destruction (rheumatologic priority)
  • Pregnant or breastfeeding patients
What to ask your clinician
  • Have I been evaluated by a dermatologist?
  • Have I had adequate trials of topical corticosteroids, vitamin D analogues, phototherapy, or biologics?
  • What evidence supports leech therapy for plaque psoriasis specifically?
  • What is the risk of Koebner phenomenon (new plaques at bite sites)?
  • What is the realistic chance of benefit, and for how long?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the cost?
  • Are leeches from an FDA-registered supplier and used only once?
When to seek urgent care
  • Rapid widespread reddening of skin (possible erythroderma — emergency)
  • Spreading pus, redness, warmth, or red streaks (cellulitis, especially with biologic users)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty
  • Rapidly spreading redness with pustules or peeling skin (suspect erythrodermic / pustular psoriasis — emergency)
  • Severe new joint pain or swelling (psoriatic arthritis flare)

What this does NOT mean

  • This is not FDA-cleared for plaque psoriasis.
  • Small, mostly uncontrolled studies and case reports do NOT establish efficacy versus evidence-based topical, phototherapy, or biologic therapies.
  • Mechanism rationale does NOT establish clinical efficacy.
  • Leech bites may trigger the Koebner phenomenon — new psoriasis plaques at bite sites.
  • Leech therapy is not a substitute for dermatology evaluation and standard psoriasis care.
  • Leech therapy does NOT address the IL-23/Th17 systemic driver of psoriasis.

Clinical Profile

Category
Dermatological
ICD-10
L40.0, L40.4, L40.8
Safety tier
Medium

Evidence Summary

No randomized, blinded trial of leech therapy for psoriasis was identified. A few small studies exist: a non-randomized comparison in Novosibirsk (Senchukova & Zhuravleva 2012; 22 patients given leech therapy plus standard dermatological treatment versus 20 given standard treatment alone) reported larger falls in mean PASI at 2 months in the leech group; an uncontrolled series of 34 children in Uzbekistan (Toshpulatov et al. 2022); and a conference abstract of 30 patients randomised to leech therapy, panchatikta ghrita or both (Gond et al. 2012). Two single-patient Ayurvedic case reports (Bhatted et al. 2023; Nagpure et al. 2025) combined leeches with other treatments. These reports are small, mostly uncontrolled, and were published outside mainstream dermatology journals, so they cannot establish that leech therapy reduces PASI or thins plaques. Any proposed local immunomodulatory mechanism is speculative and unproven. Generalized psoriasis is not appropriate for leech therapy, and standard care (topical corticosteroids, vitamin D analogues such as calcipotriol, phototherapy, and systemic or biologic agents including methotrexate for moderate-to-severe disease) remains the standard. The Koebner phenomenon (new lesions provoked at sites of skin trauma) is a genuine theoretical concern with any skin-breaking procedure. ASH position: any use of leech therapy for psoriasis is investigational and supported only by small, low-certainty clinical reports.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan mention psoriasis only in lists: in the section on the use of leeches in skin diseases, diseases of connective tissue and joints — among the conditions in which, as they write, leech treatment is recommended, and in the list of dermatological indications; the book has no separate description of psoriasis treatment with the number of patients and results, and the authors themselves note that there are few publications on hirudotherapy in such conditions (they refer to works from 1941 and 1983)[B1].
  • Further on in the same paragraph, without saying whose observations these are, which diseases from the list (and whether psoriasis) they refer to, how many patients there were, or whether they were compared with anyone, it is stated that as early as day 4–5 of treatment the skin lesions paled, the infiltrate resolved and the general condition improved, and relapses were milder; the positive effect, as it says there, continued to show for 1–3 months after the course and led to complete elimination of the clinical manifestations of the disease, whose name is not given at this point[B1].
  • Michalsen et al. do not write about leech treatment of psoriasis[B3].
  • Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, low blood pressure and acute vascular insufficiency (shock, collapse, fainting), emaciation, concurrent use of anticoagulants (especially long-term and daily), concurrent use of alcohol, individual intolerance and an extremely negative attitude of the patient toward leeches, and at high body temperature they advise refraining from leeches[B1].
  • Flecken and Michalsen, in the chapter on contraindications, call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia and bone-marrow suppression, according to them, any treatment involving blood removal is generally contraindicated; aspirin and clopidogrel are not contraindications in themselves, but at the first session they advise reducing the number of leeches and asking the patient about a tendency to bleed[B3].
  • In the appendix of Michalsen et al. (patient information and consent form), hirudotherapy is not performed, among other conditions, in blood diseases, acute gastric ulcer or erosive gastritis, immune deficiency (AIDS, chemotherapy), severe chronic diseases (advanced cancer, dialysis), a history of poor wound healing (for example, with poorly controlled diabetes, obesity and long-term cortisone treatment), known allergy to the active substances in leech saliva, and a tendency to keloids or scarring; the same document asks the patient not to use perfumed lotions, shower gels, medicinal ointments and oils on the day before and on the day of the procedure[B3].
  • Baskova and Isakhanyan consider hirudotherapy relatively contraindicated where leeches could potentially lead to cosmetic defects, and they call prescribing leeches in large numbers, for long periods, without breaks or with short breaks unjustified and impermissible[B1].
  • For people with psoriasis, including psoriasis that does not respond to other treatment, Flecken and Michalsen write nothing separately and note only the general point: in severe unstable organic disease or marked immunosuppression (they name chemotherapy) hirudotherapy is never performed, and among the severe but stable chronic diseases that they regard as relative contraindications they name connective tissue diseases, immune diseases, liver cirrhosis, dialysis and diseases of the blood-forming organs; they do not name psoriasis or the drugs that suppress immunity in it, so whether this applies to such patients is not clear from the text[B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Detailed Trial Entries

1 trial indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Erythrodermic or generalized pustular psoriasis
  • Active concomitant biologic therapy
  • Psoriatic arthritis with active joint destruction (rheumatologic primary)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.